Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572936 · ClinicalTrials.gov registry record · Phase 2
Circadian Rhythms of Aqueous Humor Dynamics in Humans
A Phase 2 study of Glaucoma, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00572936 is a Phase 2 study of Glaucoma that has completed, run by University of Nebraska. The registered enrollment target is 30 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00572936, a Phase 2 study of Glaucoma, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to identify physiological, pharmacological and pathological circadian fluctuations in aqueous humor inflow and outflow, systemic blood pressure and ocular blood flow in humans.
Conditions Studied
Interventions
- DRUG Latanoprost
- DRUG Dorzolamide
- DRUG Timolol
Study Locations (1)
Nebraska
- University of Nebraska Medical Center, Department of Ophthalmolgy and Visual Sciences - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-03-13 |
| Est. Completion | 2009-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572936
The ClinicalTrials.gov registry entry for NCT00572936 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which Latanoprost is the first listed.
NCT00572936 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT00572936 about?
NCT00572936 is a clinical study titled "Circadian Rhythms of Aqueous Humor Dynamics in Humans". This study is designed to identify physiological, pharmacological and pathological circadian fluctuations in aqueous humor inflow and outflow, systemic blood pressure and ocular blood flow in humans.
What is the current status of trial NCT00572936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-03-13. Estimated completion is 2009-11-01.
What conditions does trial NCT00572936 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT00572936?
The interventions under investigation include: Latanoprost (DRUG), Dorzolamide (DRUG), Timolol (DRUG).
Who is sponsoring clinical trial NCT00572936?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572936 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.